Adenosine in atherosclerosis

Adenosine Receptors: Therapeutic Aspects for Inflammatory and Immune Diseases

Volumn , Issue , 2006, Pages 313-323

  Reiss, Allison B ^a  

^a WINTHROP UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84871814479     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (89)

1. Libby, P., Inflammation in atherosclerosis, Nature, 420, 868, 2002.
2. Lusis, A.J., Atherosclerosis, Nature, 407, 233, 2000.
3. Leone, A., Relationship between cigarette smoking and other coronary risk factors in atherosclerosis: risk of cardiovascular disease and preventive measures, Curr. Pharm. Des., 9, 2417, 2003.
4. Hunink, M.G. et al., The recent decline in mortality from coronary heart disease, 1980-1990: the effect of secular trends in risk factors and treatment, JAMA, 277, 535, 1997.
5. Wilt, T.J. et al., Effectiveness of statin therapy in adults with coronary heart disease, Arch. Intern. Med., 164, 1427, 2004.
6. Gheisler, T. and Bhatt, D.L., The role of inflammation in atherothrombosis: current and future strategies of medical treatment, Med. Sci. Monit., 10, RA308, 2004.
7. Chan, K.Y. et al., HMG-CoA reductase inhibitors for lowering elevated levels of C-reactive protein, Am. J. Health Syst. Pharm., 61, 1676, 2004.
8. Sands, W.A. and Palmer, T.M., Adenosine receptors and the control of endothelial cell function in inflammatory disease, Immunol. Lett., 101, 1, 2005.
9. O’Regan, M., Adenosine and the regulation of cerebral blood flow, Neurol. Res., 27, 175, 2005.
10. Ralevic, V. and Burnstock, G., Receptors for purines and pyrimidines, Pharmacol. Rev., 50, 413, 1998.
11. Fredholm, B.B. et al., Nomenclature and classification of purinoceptors, Pharmacol. Rev., 46,143, 1994.
12. Dubey, R.K. et al., Cyclic AMP-Adenosine pathway inhibits vascular smooth muscle cell growth, Hypertension, 28, 765, 1996.
13. Jennings, L.L. et al., Adenosine transport: recent advances in the molecular biology of nucleoside transporter proteins, Drug. Dev. Res., 45, 277, 1998.
14. Ontyd, J. and Schrader, J., Measurement of adenosine, inosine, and hypoxanthine in human plasma, J. Chromatogr., 307, 404, 1984.
15. Moser, G.H., Schrader, J., and Deussen, A., Turnover of adenosine in plasma of human and dog blood, Am. J. Physiol., 256, C799, 1989.
16. Schrader, J., Formation and metabolism of adenosine and adenine nucleotides in cardiac tissue, in Phillis, J.W., Ed., Adenosine and Adenine Nucleotides as Regulators of Cellular Function, Boca Raton, FL: CRC Press, 1991, pp. 55-69.
17. Borst, M.M. and Schrader, J., Adenine nucleotide release from isolated perfused guinea pig hearts and extracellular formation of adenosine, Circ. Res., 68, 797, 1991.
18. Dubey, R.K. et al., Smooth muscle cell-derived adenosine inhibits cell growth, Hypertension, 27, 766, 1996.
19. Smolenski, R.T. et al., Endothelial nucleotide catabolism and adenosine production, Cardiovasc, Res., 28, 100, 1994.
20. Gordon, E.L. et al., The hydrolysis of extracellular adenine nucleotides by arterial smooth muscle cells: regulation of adenosine production at the cell surface, J. Biol. Chem., 264, 18986, 1989.
21. 2B receptor, Hypertension, 27, 786, 1996.
22. Shryock, J.L. and Belardinelli, L., Adenosine and adenosine receptors in the cardiovascular system: biochemistry, physiology, and pharmacology, Am. J. Cardiol., 79, 2, 1997.
23. 2A adenosine receptor agonists, Am. J. Cardiol., 94, 33D, 2004.
24. Treasure, C.B. et al., Endothelium-dependent dilation of the coronary microvasculature is impaired in dilated cardiomyopathy, Circulation, 81, 772, 1990.
25. Daut, J. et al., Hypoxic dilation of coronary arteries is mediated by ATP-sensitive potassium channels, Science, 247, 1341, 1990.
26. 2 receptors and cAMP-dependent protein kinase, Proc. Natl. Acad. Sci. U.S.A., 92, 12441, 1995.
27. Sato, A. et al., Mechanism of vasodilation to adenosine in coronary arterioles from patients with heart disease, Am. J. Physiol. Heart Circ. Physiol., 288, H1633, 2005.
28. Teng, B. et al., Involvement of p38-Mitogen-activated protein kinase (MAPK) in adenosine-receptor mediated relaxation of coronary artery, Am. J. Physiol. Heart Circ. Physiol., 288, H2574, 2005.
29. Jonzon, B., Nilsson, J., and Fredholm, B.B., Adenosine receptor-mediated changes in cyclic AMP production and DNA synthesis in cultured arterial smooth muscle cells. J. Cell. Physiol., 124, 451, 1985.
30. Takiguchi, Y. et al., Early administration of YT-146, an adenosine A2 receptor agonist, inhibits neointimal thickening after rat femoral artery endothelium injury, Eur. J. Pharmacol., 281, 205, 1995.
31. Dubey, R.K. et al., Endogenous cyclic AMP-adenosine pathway regulates cardiac fibroblast growth, Hypertension, 37, 1095, 2001.
32. Ross, R., Atherosclerosis: an inflammatory disease, N. Engl. J. Med., 340, 115, 1999.
33. Granger, D.N., Vowinkel, T., and Petnehazy, T., Modulation of the inflammatory response in cardiovascular disease, Hypertension, 43, 924, 2004.
34. 2B receptor activation, J. Exp. Med., 188, 1433, 1998.
35. Burnstock, G., Release of vasoactive substances from endothelial cells by shear stress and purinergic mechanosensory transduction, J. Anat., 194, 335, 1999.
36. Bodin, P. and Burnstock, G., Purinergic signalling: ATP release, Neurochem. Res., 26, 959, 2001.
37. Iwamoto, T. et al., Identification of adenosine A2 receptor-cAMP system in human aortic endothelial cells, Biochem. Biophys. Res. Commun., 199, 905, 1994.
38. Linden, J., Molecular approach to adenosine receptors: receptor-mediated mechanisms of tissue protection, Annu. Rev. Pharmacol. Toxicol., 41, 775, 2001.
39. Van Daele, P. et al., Effects of adenine nucleotides on the proliferation of aortic endothelial cells, Circ. Res., 70, 82, 1992.
40. Harrington, E.O. et al., Barrier dysfunction and RhoA activation are blunted by homocysteine and adenosine in pulmonary endothelium, Am. J. Physiol. Lung Cell Mol. Physiol., 287, L1091, 2004.
41. Headrick, J.P. and Berne, R.M., Endothelium-dependent and -independent relaxations to adenosine in guinea pig aorta, Am. J. Physiol., 259, H62, 1990.
42. Zanzinger, J. and Bassenge, E., Coronary vasodilation to acetylcholine, adenosine and bradykinin in dogs: effects of inhibition of NO-synthesis and captopril, Eur. Heart J., 14, 164, 1993.
43. Smits, P. et al., Endothelial release of nitric oxide contributes to the vasodilator effect of adenosine in humans, Circulation, 92, 2135, 1995.
44. Nees, S., The adenosine hypothesis of metabolic regulation of coronary flow in the light of newly recognized properties of the coronary endothelium, Z. Kardiol., 6, 42, 1989.
45. Ray, C. et al., Interactions of adenosine, prostaglandins and NO in hypoxia-induced vasodilatation: in vivo and in vitro studies, J. Physiol., 544, 195, 2002.
46. Edmunds, N.J., Moncada, S., and Marshall, J.M., Does nitric oxide allow endothelial cells to sense hypoxia and mediate hypoxic vasodilatation? In vivo and in vitro studies, J. Physiol., 546, 521, 2003.
47. Cornwell, T.L. et al., Inhibition of smooth muscle cell growth by nitric oxide and activation of cAMP-dependent protein kinase by cGMP, Am. J. Physiol., 267, C1405, 1994.
48. Sarkar, R., Webb, R.C., and Stanley, J.C., Nitric oxide inhibition of endothelial cell mitogenesis and proliferation, Surgery, 118, 274, 1995.
49. de Graaf, J.C. et al., Nitric oxide functions as an inhibitor of platelet adhesion under flow conditions, Circulation, 85, 2284, 1992.
50. Gauthier, T.W. et al., Nitric oxide protects against leukocyte-endothelium interactions in the early stages of hypercholesterolemia, Arterioscler. Thromb. Vasc. Biol., 15, 1652, 1995.
51. Palmer, R.M.J. et al., L-Arginine is the physiological precursor for the formation of nitric oxide in endothelium-dependent relaxation, Biochem. Biophys. Res. Commun., 153, 1251, 1988.
52. Hein, T.W. and Kuo, L., cAMP-independent dilation of coronary arterioles to adenosine:role of nitric oxide, G proteins, and K(ATP) channels, Circ. Res., 85, 634, 1999.
53. Hein, T.W., Belardinelli, L., and Kuo, L., Adenosine A(2A) receptors mediate coronary microvascular dilation to adenosine: role of nitric oxide and ATP-sensitive potassium channels, J. Pharmacol. Exp. Ther., 291, 655, 1999.
54. Rubio, R. and Ceballos, G., Sole activation of three luminal adenosine receptor subtypes in different parts of coronary vasculature, Am. J. Physiol. Heart Circ. Physiol., 284, H204, 2003.
55. Arnold, W.P. et al., Nitric oxide activates guanylate cyclase and increases guanosine 3′:5′ -cyclic monophosphate levels in various tissue preparations, Proc. Natl. Acad. Sci. U.S.A., 74, 3203, 1977.
56. Murphy, M.E. and Brayden, J.E., Nitric oxide hyperpolarizes rabbit mesenteric arteries via ATP-sensitive potassium channels, J. Physiol., 486, 47, 1995.
57. Bolotina, V.M. et al., Nitric oxide directly activates calcium-dependent potassium channels in vascular smooth muscle, Nature, 368, 850, 1994.
58. Dawicki, D.D. et al., Extracellular ATP and adenosine cause apoptosis of pulmonary artery endothelial cells, Am. J. Physiol., 273, L485, 1997.
59. Ferroni, P., Basili, S., and Davi, G., Platelet activation, inflammatory mediators and hypercholesterolemia, Curr. Vasc. Pharmacol., 1, 157, 2003.
60. Gawaz, M., Platelets and the pathophysiology of coronary heart disease, in Blood Platelets, Physiology, Pathophysiology, Membrane Receptor, Antiplatelet Principles, and Therapy for Atherothrombotic Diseases, Stuttgart, Germany: Georg Thieme Verlag, 2001, pp. 97-118.
61. Libby, P. et al., Production of platelet derived growth factor-like mitogen by smooth muscle cells from human atheroma, N. Engl. J. Med., 318, 1493, 1988.
62. Gawaz, M. et al., Platelets induce alterations of chemotactic and adhesive properties of endothelial cells mediated through an interleukin-1-dependent mechanism: implications for atherogenesis, Atherosclerosis, 148, 75, 2000.
63. 2receptor subtypes, Mol. Pharmacol., 43, 909, 1993.
64. 2receptor agonists on platelet aggregation in the rabbit, Eur. J. Pharmacol., 259, 43, 1994.
65. 2receptor ligand [3H]CGS 21680 to human platelet membranes, Biochem. Pharmacol., 48,1658, 1994.
66. 2a receptor, Nature, 388, 674, 1997.
67. Varani, K. et al., Dose and time effects of caffeine intake on human platelet adenosine A(2A) receptors: functional and biochemical aspects, Circulation, 102, 285, 2000.
68. Gasser, J.A. et al., Decreased sensitivity to adenosine in platelets from patients with familial hypercholesterolaemia-a change reversed by cholestyramine treatment, Eur. J. Clin. Invest., 23, 803, 1993.
69. Dawicki, D.D., Agarwal, K.C., and Parks, R.E., Role of adenosine uptake and metabolism by blood cells in the antiplatelet actions of dipyridamole, dilazep and nitrobenzylthioinosine, Biochem. Pharmacol., 34, 3965, 1985.
70. Riboldi, P. et al., Cardiac involvement in systemic autoimmune diseases, Clin. Rev. Allergy Immunol., 23, 247, 2002.
71. Cronstein, B.N., Naime, D., and Ostad, E., The anti-inflammatory effects of methotrexate are mediated by adenosine, Adv. Exp. Med. Biol., 370, 411, 1994.
72. Cronstein, B.N., Adenosine, an endogenous anti-inflammatory agent, J. Appl. Physiol., 76, 5, 1994.
73. Choi, H.K. et al., Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study, Lancet, 359, 1173, 2002.
74. Libby, P., Current concepts of the pathogenesis of the acute coronary syndromes, Circulation, 104, 365, 2001.
75. 2A receptor occupancy stimulates expression of proteins involved in reverse cholesterol transport and inhibits foam cell formation in macrophages, J. Leukocyte Biol., 76, 727, 2004.
76. Lund, E. et al., Importance of a novel oxidative mechanism for elimination of intracellular cholesterol in humans, Arterioscler. Thromb. Vasc. Biol., 16, 208, 1996.
77. Costet, P. et al., Sterol-dependent transactivation of the ABC1 promoter by the liver X receptor/retinoid X receptor, J. Biol. Chem., 275, 28240, 2000.
78. Fu, X. et al., 27-Hydroxycholesterol is an endogenous ligand for LXR in cholesterolloaded cells, J. Biol. Chem., 276, 38378, 2001.
79. Langmann, T. et al., Molecular cloning of the human ATP-binding cassette transporter 1 (hABC1): evidence for sterol-dependent regulation in macrophages, Biochem. Biophys. Res. Commun., 257, 29, 1999.
80. Rust, S. et al., Tangier disease is caused by mutations in the gene encoding ATPbinding cassette transporter 1, Nat. Genet., 22, 352, 1999.
81. Reiss, A.B. et al., Immune complexes and interferon-γ decrease cholesterol 27- hydroxylase in human arterial endothelium and macrophages, J. Lipid Res., 42, 1913, 2001.
82. 2 receptor activation attenuates reperfusion injury by inhibiting neutrophils accumulation, superoxide generation, and coronary endothelial adherence, J. Pharmacol. Exp. Ther., 280, 301, 1997.
83. Kitakaze, M. et al., Adenosine and cardioprotection in the diseased heart, Jpn. Circ. J., 63, 231, 1999.
84. Glover, D.K. et al., Reduction of infarct size and postischemic inflammation from ATL-146e, a highly selective adenosine A2A receptor agonist, in reperfused canine myocardium, Am. J. Physiol., 288, H1851, 2005.
85. 4+T cells, J. Immunol., 174, 1073, 2005.
86. Saransaari, P. and Oja, S.S., Enhanced release of adenosine under cell-damaging conditions in the developing and adult mouse hippocampus, Neurochem. Res., 28, 1409, 2003.
87. 2-) release by activated human neutrophils, Clin. Immunol. Immunopathol., 42, 76, 1987.
88. McCord, J.M., Oxygen-derived free radicals: a link between reperfusion injury and inflammation, Fed. Proc., 46, 2402, 1987.
89. Zmijewski, J.W. et al., Oxidized low density lipoprotein induces mitochondrially associated reactive oxygen/nitrogen species formation in endothelial cells, Am. J. Physiol. Heart Circ. Physiol., 289, H852, 2005.